Loading [MathJax]/extensions/MathML/content-mathml.js
info@auctorespublishing.com
+1-(302)-520-2644
+1-(302)-520-2644

BMAC and Adipose-Derived MSCs Treatment for Knee Osteoarthritis: A Systematic Review

  1. Home
  2. Journals
  3. International Journal of Clinical Case Reports and Reviews
  4. Archives
Submit Guidelines

Review Article | DOI: https://doi.org/10.31579/2690-4861/150

BMAC and Adipose-Derived MSCs Treatment for Knee Osteoarthritis: A Systematic Review

  • Pooja Pithadia MSc * 1
  • Sharmila Tulpule MBBS, M.S, MCh Ortho 2
  • Masud ur Rahman MBBS, FRCS 3
  • Mrinalini Singh PhD 4
  • 1 Medical Biotechnology, Medica Pain Management Clinic, London,UK
  • 2 Medica Stem Cells, Dubai, UAE.
  • 3 Medica Stem Cells, Dublin, Ireland.
  • 4 Medica Institute Pvt Ltd, India.

*Corresponding Author: Pooja Pithadia, Medical Biotechnology, Medica Pain Management Clinic, London, UK.

Citation: P Pithadia, S Tulpuele, M Rahman, M Singh. (2021) BMAC and Adipose-Derived MSCs Treatment for Knee Osteoarthritis: A Systematic Review. International Journal of Clinical Case Reports and Reviews. 7(5); DOI: 10.31579/2690-4861/150

Copyright: © 2021 Pooja Pithadia, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 18 June 2021 | Accepted: 14 July 2021 | Published: 17 July 2021

Keywords: bmac; stromal vascular fraction; adipose-derived mesenchymal stem cells; bone marrow aspirate concentrate; svf; knee osteoarthritis

Abstract

Background: Knee osteoarthritis is the most common musculoskeletal progressive disorder that affects nearly 303 million people worldwide. This condition prevails in 10% males and 13% females among the elders above 60. Although there is conventional nonsurgical and surgical treatment available for knee osteoarthritis, there is a fascinating interest in bone marrow aspirate concentrate (BMAC) as well as adipose-derived mesenchymal stem cells (AD-MSC), including enzymatically treated stromal vascular fraction (SVF) and mechanically treated (microfat/nanofat) injections among physicians. Hence, this systematic review aims to determine the efficacy of BMAC and AD-MSCs (enzyme and mechanically treated) injections for knee osteoarthritis treatment.

Methods: A systematic review was performed on the following data sources (PubMed, Scopus, Google Scholar, EMBASE, and Cochrane Library) published on March 31, 2021. The keywords or MeSH terms include 'Knee Osteoarthritis with 'Bone marrow aspirate concentrate' OR 'BMAC' or with 'Adipose-derived mesenchymal stem cells (AD-MSC)' or with 'Stromal vascular fraction' OR 'SVF' or 'Mechanically treated AD-MSC (mfat/nanofat)'. In addition, the retrieved articles were further reviewed to identify relevant research studies.

Results: The authors reviewed and tabulated data based on the year of study, study type, therapy protocol, patient population, outcome measures, and interpretation. Among the 382 records screened, 43 studies (16 on BMAC and 27 on AD-MSCs) were included in the systematic review study. Among them, only 5 were randomized controlled trials. These selected studies demonstrated short-term positive outcomes such as improvement in knee pain and function with no adverse side effects. Moreover, researchers reported varied administration methods of BMAC or AD-MSC either as standalone or in combination with other conservative procedures such as PRP (Platelets Rich Plasma), HA (Hyaluronic acid), or surgery.

Conclusions: BMAC and AD-MSC (enzymatically and mechanically treated) injections prove safer and more efficacious in patients with knee osteoarthritis for a shorter duration of 2 years. However, the available literature lacks high-quality studies with no varied clinical settings and long-term follow-up of more than two years.

Introduction

Osteoarthritis (OA) is the most common type of progressive musculoskeletal arthritic disorder affecting nearly 303 million people worldwide [1]. Compared to all the joint regions, OA commonly affects hip and knee joints [2]. Due to a steady increase in ageing, obesity, and life expectancy, knee OA is prevalent in 10% males and 13

Methods

This systematic review was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [17,18].

A comprehensive, systematic literature search was performed in April 2021, and an analysis of these articles was conducted by all the authors involved in the study. The databases of PubMed, Scopus, Google Scholar, EMBASE, and Cochrane Library were searched from 2011 to March 31, 2021. The following keywords were used in different combinations: 'Knee Osteoarthritis with 'Bone marrow aspirate concentrate' OR 'BMAC' or 'Adipose-derived mesenchymal stem cells or 'Stromal vascular fraction' OR 'SVF' or 'Mechanically treated AD-MSC (mfat/nanofat)'.

Study selection 

All participants in the trials had to have a clinical diagnosis of knee osteoarthritis under either intra-articular BMAC or AD-MSCs treatment. 

We limited the search to articles in English, and only human studies were included. After assessing all titles and abstracts, all relevant articles were obtained. Even the bibliographies were also searched to identify further relevant literature that met our inclusion criteria.

All studies were included if their design could be classified into one of the following categories: open-label, randomized controlled trial, prospective, retrospective study, and pilot study. 

We included studies in which adult participants were diagnosed with knee osteoarthritis by clinical or image evaluation. We excluded articles lacking access to the full text, conference presentations, narrative reviews, editorials, and expert opinions. 

The articles found were pooled and subjected to inclusion and exclusion criteria established before the commencement of this systematic review. A PRISMA flowchart of this systematic review is provided in Figure I.

Data extraction 

The researchers independently recorded the study design, therapy protocol, patient population, outcome measures, and interpretations. 

Figure 1: A flow diagram of study inclusions: BMAC and AD-MSCs [PRISMA 2009 flow diagram]

Results

Literature search

Of the 382 articles initially identified by the search, 16 [19,30,32,35] on BMAC and 27 [36,62,16]. on AD-MSCs, including SVF, met the inclusion criteria. Therefore, the relevant data is given in Tables III and IV.

Participants

The 16 studies under BMAC involved 10 to 681 patients with the age group of between 18-85 affected by knee OA [Table I), while 27 studies under AD-MSCs, including SVF, involved 2 to 2586 knee OA patients between 18-89 age group [Table II]. Among these 44 studies, only 5 were randomized controlled trials. Fourteen papers were prospective studies, with three of them being comparative, two being open-label, one being a pilot study. The rest were retrospective studies, with two of them being comparative.

Therapeutic approaches

Regarding the therapeutic protocol, BMAC was either injected alone or combined with PRP in the same session, alternatively as a booster dose after a certain period. Very few authors injected BMAC in association with adipose tissue or scaffold. Under AD-MSCs, it was either injected alone or combined with PRP, adipose tissue, HA, or scaffold.

Outcome measures

Regarding outcomes, varied clinical scores such as WOMAC, VAS, KOOS, IKDC, KSS, ICOAP, NPS, and LEFS were used to evaluate the outcomes of BMAC injections (Table 1) and AD-MSCs injections (Table 2). Even MRI was performed before and after the procedure to detect positive changes in the resultant images. Very few authors used ICRS, OKS, NRS, ROM, Tegner activity, Lysholm patient satisfaction scores, and PROMIS questionnaires. Immunohistochemical analysis was reported only in Roato et al. 55. 's study involving AD-MSCs injections. 

Table I: Patients' demographics [BMAC]
Table II: Patients' demographics [AD-MSCs]
Table III: Clinical studies regarding the use of BMAC to treat knee osteoarthritis
Table IV: Clinical studies regarding the use of AD-MSCs to treat knee osteoarthritis

Safety and efficacy of BMAC and AD-MSCs therapy 

None of the studies analyzed in this systematic review recorded any complication or adverse effect of BMAC and AD-MSCs administration. Only mild pain and swelling have been observed in very few patients within the initial few days following BMAC/AD-MSCs injection procedure. Furthermore, both BMAC and AD-MSCs showed positive clinical outcomes with significant improvement in pain, articular function, and range of movement.

Discussion

The results of this systematic review validate that both BMAC and AD-MSCs treatments are safe and effective to treat knee OA. However, the therapeutic use of BMAC and AD-MSCs, especially SVF, is restricted across the United States, Europe, and many other countries based on safety and efficacy concerns.

The significant finding of this systematic review is that most of the studies are of low quality with a lack of well-defined methodologies, with very few RCTs, thus preventing us from providing any substantial conclusions on the therapeutic potential of these AD-MSCs and BMAC injections. 

Furthermore, there is an inadequate patient selection process, although these studies reported good reliability. The inclusion and exclusion criteria, recruitment rate, and a well-defined selection process were rarely reported. Hence, further studies including larger patient cohorts should be performed to demonstrate the long-term effect of both BMAC and AD-MSCs injections. 

Many patients underwent conservative treatments such as steroid treatment or surgical procedures in most of these studies, such as microfracture, arthroscopic debridement, or high tibial osteotomy. Hence there is no clear understanding of the exclusive clinical potential of these BMAC and AD-MSCs injections.

We can find the release of platelet-rich plasma (PRP) treatment without adequate evidence in the recent past. This treatment has been used clinically due to high media exposure only [61]. There is a possibility to exempt 510(k) regulations [62]. New medical devices "substantially equivalent" to those already prevalent in the market can skip the standard FDA approval process. Hence, there was an increase in the production of PRP kits. However, this market saturated due to overproduction by various preparation systems, thereby preventing a "standardization" of PRP therapy for knee OA treatment.

This same scenario is now approaching AD-MSCs and BMAC therapies that are not affected by the regulatory burden. Moreover, they can be quickly harvested from the OA patient and administered immediately through an intra-articular injection with PRP or HA (hyaluronic acid). HA provides an environment where MSCs can easily adhere to the target area around the lesion and differentiate into cells to build damaged bone and cartilage. Similarly, PRP consists of highly concentrated platelets and varied growth factors to exacerbate the proliferation of MSCs [68,69]. Hence, this simultaneous use of other biological agents or administering these treatments following the conventional procedures prevent a reasonable comparison of the studies performed so far. 

The available RCTs have several biases since most of the patients were treated bilaterally [20,63]. This is not the ideal condition to determine the efficacy of a treatment since the patients cannot evaluate one knee independently from the other. There was no proper clarity on the number of cells administered and the exact number of injections for the best outcome. It was even difficult to interpret which one of the two treatments provide better outcomes. Although their immunophenotypes are more than 90% identical [64,65], they still have many distinct characteristics, especially in their cell surface markers, differentiation potentials, and distribution within the body. An in vitro analysis revealed that almost 300-fold more SVF can be derived from 100 g of adipose tissue when compared to 100 ml of bone marrow aspirate [66,67]. However, there is no apparent connection between the quantity and the dose-effect. Furthermore, there is no substantial evidence to define the patient's profile that could respond better to a specific treatment compared to others. Hence, this topic demands more research to understand the effect of both BMAC and AD-MSCs therapies.

Both bone marrow harvesting and lipoaspiration are minimally invasive procedures with minimal side effects. However, lipoaspiration was more severe due to the associated risks of pain and hematoma. Anyway, the surgeon who opts for these treatments depends on the availability of preparation kits in different countries. Moreover, industries have been releasing their proprietary kits for BMAC and AD-MSCs preparation, with new methods still being developed. However, there is no adequate research evidence to support the ability of MSCs.

At present, stem cell treatment is expensive and cannot be considered a "routine" treatment for knee cartilage degeneration. From a clinical viewpoint, the use of BMAC and AD-MSCs for knee OA treatment seems to be safe and deliver positive clinical outcomes. Moreover, this treatment can be a minimally invasive therapeutic option for patients who are ineligible for surgery. However, their promising outcomes for a shorter duration (3 months–24 months) must sustain for the long term of more than two years compared to the available conventional treatments. Hence, the use of BMAC or AD-MSCs therapies must be thoroughly discussed between the physician and the patient before proposing them as a first-line therapeutic approach to avoid surgery.

However, increasing the number of treatment options for knee OA does not always intend to improve the standard of care, especially when there is a lack of enough comparative trials that determine the effectiveness of a novel treatment compared to established ones.

Limitations

It is possible that BMAC and AD-MSCs injections could deliver positive outcomes in treating knee osteoarthritis, according to the results from our study. Nonetheless, the factors affecting the outcomes are but not limited to the lack of control group, a small number of studies and co-interventions, a small sample size, lack of long-term follow-up of not more than two years, the possibility of bias, and lack of objective assessment on the interventions 

Although these above findings provide encouraging results, the lack of comparative study with corticosteroids and hyaluronic acid limits definitive conclusions, furthermore, the relationship of sex, age, and the severity of knee osteoarthritis could not be figured out clearly.

Additionally, MRI evaluation was not performed in all the studies to complement the clinical parameters, including the quantification of knee cartilage regeneration following the treatment. Moreover, there is a lack of comparison among the outcomes for different KL grades. Hence, more studies are required to confirm the positive long-term effects of AD-MSCs and BMAC therapies for knee osteoarthritis.

Despite having all these limitations, the treatment of knee osteoarthritis with BMAC and AD-MSCs seems to be safe by delivering positive clinical outcomes. This treatment can be a potential minimally invasive option for those who are ineligible for invasive approaches. 

Conclusion

BMAC and AD-MSCs injections prove safer and more efficacious in treating knee osteoarthritis on a short-term duration (3 months-24 months) without any adverse side effects. However, only very few randomized control studies are published to support this result. Additionally, there is a lack of high-quality research studies for more than 2 years with varied trial settings.

List of abbreviations

References

  1. Kloppenburg M, Berenbaum F. (2020) Osteoarthritis year in review 2019: Epidemiology and therapy. Osteoarthr Cartil. 28: 242-248.
    View at Publisher | View at Google Scholar
  2. Bortoluzzi A, Furini F, Scirè CA. (2018) Osteoarthritis and its management- Epidemiology, nutritional aspects and environmental factors. Autoimmun Rev. 1097-1104.
    View at Publisher | View at Google Scholar
  3. Moghimi N, Rahmani K, Delpisheh A, Saidi A, Azadi NA, et al. (2019) Risk factors of knee osteoarthritis: A case-control study. Pakistan J Med Sci. 35: 636-640.
    View at Publisher | View at Google Scholar
  4. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. (2012) Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 64:1697-707.
    View at Publisher | View at Google Scholar
  5. Park H, Kim H, Lee Y. (2020) Knee osteoarthritis and its association with mental health and health-related quality of life: A nationwide cross-sectional study. Geriatr Gerontol Int. 20: 379-383.
    View at Publisher | View at Google Scholar
  6. Anandacoomarasamy A, March L. (2010) Current evidence for osteoarthritis treatments. Ther Adv Musculoskelet Dis; 2:17-28.
    View at Publisher | View at Google Scholar
  7. Fodor PB, Paulseth SG. (2016) Adipose-Derived Stromal Cell (ADSC) Injections for Pain Management of Osteoarthritis in the Human Knee Joint. Aesthet Surg J. 36(2):229-236.
    View at Publisher | View at Google Scholar
  8. Wehling P, Evans C, Wehling J, et al. (2017) effectiveness of intra-articular therapies in osteoarthritis: a literature review. Ther Adv Musculoskelet Dis. 9(8): 183-196.
    View at Publisher | View at Google Scholar
  9. Laudy AB, Bakker EW, Rekers M, Moen MH. (2015) Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis. Br J Sports Med. 49(10):657-672.
    View at Publisher | View at Google Scholar
  10. Rabago D, Patterson JJ, Mundt M, Zgierska A, Fortney L, et al. (2014) Dextrose and morrhuate sodium injections (prolotherapy) for knee osteoarthritis: a prospective open-label trial. J Altern Complement Med. 20: 383-391.
    View at Publisher | View at Google Scholar
  11. A. M. DiMarino, A. I. Caplan, and T. L. (2013) Bonfield. Mesenchymal stem cells in tissue repair. Frontiers in Immunology. 4:201.
    View at Publisher | View at Google Scholar
  12. Caplan AI, Correa D. (2011) The MSC: an injury drugstore. Cell Stem Cell. 9(1):11-15.
    View at Publisher | View at Google Scholar
  13. Caplan AI. (2007) Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. Journal of Cellular Physiology. 213(2):341-347.
    View at Publisher | View at Google Scholar
  14. Filardo G, Madry H, Jelic M, Roffi A, Cucchiarini M, and Kon E. (2013) Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics. Knee Surgery, Sports Traumatology, Arthroscopy. 21(8):1717-1729.
    View at Publisher | View at Google Scholar
  15. Kristin S. Oliver, MD, Matthew Bayes, MD, David Crane, Chakrapani Pathikonda. (2015) Clinical outcome of bone marrow concentrates in knee osteoarthritis. Journal of Prolotherapy. 7:937-946.
    View at Publisher | View at Google Scholar
  16. Zhang et al. (2021) Intra-Articular Injection of Autologous Adipose-Derived Stromal Vascular Fractions for the Cartilage Repair of Grade 2 and 3 Knee Osteoarthritis: A Confirmatory Clinical Trial. Research Square. 1-24.
    View at Publisher | View at Google Scholar
  17. Liberati A, Altman DG, Tetzlaff J, et al. (2009) The PRISMA statement for reporting systematic reviews and meta analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ.
    View at Publisher | View at Google Scholar
  18. Moher D, Liberati A, Tetzlaff J, et al. (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ.
    View at Publisher | View at Google Scholar
  19. Shapiro SA, Kazmerchak SE, Heckman MG, Zubair AC, O Connor MI, et al. (2017) A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis. Am J Sports Med. 45(1): 82-90.
    View at Publisher | View at Google Scholar
  20. Shapiro SA, Arthurs JR, Heckman MG, et al. (2019) Quantitative T2 MRI mapping and 12-month follow-up in a randomized, blinded, placebo-controlled trial of bone marrow aspiration and concentration for osteoarthritis of the knees. Cartilage. 10(4):432-443.
    View at Publisher | View at Google Scholar
  21. Kim J Do, Lee GW, Jung GH, Kim CK, Kim T, et al. (2014) Clinical outcome of autologous bone marrow aspirates concentrate (BMAC) injection in degenerative arthritis of the knee. Eur J Orthop Surg Traumatol. 24(8): 1505-1511.
    View at Publisher | View at Google Scholar
  22. Sampson S, Smith J, Vincent H, Aufiero D, Zall M, et al. (2016) Intraarticular bone marrow concentrate injection protocol: short-term efficacy in osteoarthritis. Regen Med. 11(6): 511-520.
    View at Publisher | View at Google Scholar
  23. Krych AJ, Nawabi DH, Farshad Amacker NA, Jones KJ, Maak TG, et al. (2016) Bone Marrow Concentrate Improves of a Scaffold Plug in the knee. Am J Sports Med. 44(1): 89-91.
    View at Publisher | View at Google Scholar
  24. Anz A, Hubbard R. (2020) Bone Marrow Aspirate Concentrate Is Equivalent to Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis at 1 Year: A Prospective, Randomized Trial. Orthrop J Sports Med.8(2).
    View at Publisher | View at Google Scholar
  25. Centeno C, Pitts J, Al-Sayegh H, Freeman M. (2014) Efficacy of autologous bone marrow concentrate for knee osteoarthritis with and without adipose graft. Biomed Res Int. 2014:370621.
    View at Publisher | View at Google Scholar
  26. Centeno CJ, Al-Sayegh H, Bashir J, Goodyear S, Freeman MD. (2015) A dose response analysis of a specific bone marrow concentrate treatment protocol for knee osteoarthritis. BMC Musculoskelet Disord. 16:258.
    View at Publisher | View at Google Scholar
  27. Rodriguez-Fontan F, Piuzzi N, Kraeutler M, Pascual-Garrido C. (2018) Early Clinical Outcome of Intra-Articular Injections of Bone Marrow Aspirate Concentrate for the Treatment of Early Osteoarthritis of the Hip and Knee: A Cohort Study. PM R. 10(12):1353-1359.
    View at Publisher | View at Google Scholar
  28. Themistocleous G, Chloros G, Kyrantzoulis I, et al. (2018) Effectiveness of a single intraarticular bone marrow aspirate concentrate (BMAC) injection in patients with grade 3 and 4 knee osteoarthritis. Heliyon. 4(10).
    View at Publisher | View at Google Scholar
  29. Ryu DJ, Jeon YS, Park JS, Bae GC, Kim J, et al. (2020) Comparison of Bone Marrow Aspirate Concentrate and Allogenic Human Umbilical Cord Blood Derived Mesenchymal Stem Cell Implantation on Chondral Defect of Knee: Assessment of Clinical and Magnetic Resonance Imaging Outcomes at 2-Year Follow-Up. Cell Transplant.
    View at Publisher | View at Google Scholar
  30. Kristin S. Oliver, Matthew Bayes, David Crane, Chakrapani Pathikonda. (2015) Clinical Outcome of Bone Marrow Concentrate in Knee Osteoarthritis. Journal of Prolotherapy.937-946.
    View at Publisher | View at Google Scholar
  31. Bianchi F, Maioli M, Leonardi E, Olivi E, Pasquinelli G, et al. (2013) A new nonenzymatic method and device to obtain a fat tissue derivative highly enriched in pericyte-like elements by mild mechanical forces from human lipoaspirates. Cell Transplantation. 22: 2063-2077.
    View at Publisher | View at Google Scholar
  32. Oliver K, Bayes M, Crane D, Pathikonda C. (2015) Clinical outcome of bone marrow concentrate in knee osteoarthritis. J Prolotherapy.
    View at Publisher | View at Google Scholar
  33. Shaw B., Darrow M., and A. Derian. (2018) Short-term outcomes in treatment of knee osteoarthritis with 4 bone marrow concentrate injections. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders.
    View at Publisher | View at Google Scholar
  34. Vad V, Barve R, Linnell E, Harrison J. (2016) Knee osteoarthritis treated with percutaneous chondral-bone interface optimization: a pilot trial. Surgical Science. 7(1): 1-12.
    View at Publisher | View at Google Scholar
  35. Hernigou P., Auregan J. C., Dubory A., Flouzat-Lachaniette C. H., Chevallier N., and Rouard H. (2018) Subchondral stem cell therapy versus contralateral total knee arthroplasty for osteoarthritis following secondary osteonecrosis of the knee. International Orthopaedics. 42(11):2563-2571.
    View at Publisher | View at Google Scholar
  36. Gibbs N, Diamond R, Sekyere EO, Thomas DW. (2015) Management of knee osteoarthritis by combined stromal vascular fraction cell therapy, platelet-rich plasma and musculoskeletal exercises: a case series. J Pain Res.8: 799-806.
    View at Publisher | View at Google Scholar
  37. Bansal H, Comella K, Leon J, et al. (2017) Intra-articular injection in the knee of adipose derived stromal cells (stromal vascular fraction) and platelet rich plasma for osteoarthritis. J Transl Med. 15(1):141.
    View at Publisher | View at Google Scholar
  38. Garza J, Maria D, Palomera T, Dumanian G, Anjos S. (2015) Use of Autologous AdiposeDerived Stromal Vascular Fraction to Treat Osteoarthritis of the Knee: A Feasibility and Safety Study. J Regen Med.
    View at Publisher | View at Google Scholar
  39. Hong Z, Chen J, Zhang S, et al. (2019) Intra-articular Injection of Autologous Adipose-Derived Stromal Vascular Fractions for Knee Osteoarthritis: A Double-Blind Randomized Self Controlled Trial Int Orthop. 43(5):1123-1134.
    View at Publisher | View at Google Scholar
  40. Mautner K, Bowers R, Easley K, Fausel Z, Robinson R. (2019) Functional Outcomes Following Microfragmented Adipose Tissue Versus Bone Marrow Aspirate Concentrate Injections for Symptomatic Knee Osteoarthritis. Stem Cells Transl Med. 8(11):1149-1156.
    View at Publisher | View at Google Scholar
  41. Pak J. (2011) Regeneration of human bones in hip osteonecrosis and human cartilage in knee osteoarthritis with autologous adipose-tissue-derived stem cells: a case series. J Med Case Rep. 5:296
    View at Publisher | View at Google Scholar
  42. Pak J, Chang JJ, Lee JH, Lee SH. (2013) Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints. BMC Musculoskelet Disord. 14:337.
    View at Publisher | View at Google Scholar
  43. Pak J, Lee JH, Park KS, Jeong BC, Lee SH. (2016) Regeneration of cartilage in human knee osteoarthritis with autologous adipose tissue-derived stem cells and autologous extracellular matrix. Biores Open Access. 5:192–200
    View at Publisher | View at Google Scholar
  44. Pintat J, Silvestre A, Magalon G, et al. (2017) Intra-articular Injection of Mesenchymal Stem Cells and Platelet-Rich Plasma to Treat Patellofemoral Osteoarthritis: Preliminary Results of a Long-Term Pilot Study. J Vasc Interv Radiol. 28(12):1708-1713.
    View at Publisher | View at Google Scholar
  45. Yokota N, Yamakawa M, Shirata T, Kimura T, Kaneshima H. (2017) Clinical results following intra-articular injection of adipose-derived stromal vascular fraction cells in patients with osteoarthritis of the knee. Regen Ther. 6:108-112.
    View at Publisher | View at Google Scholar
  46. Hudetz D, Borić I, Rod E, Jeleč Ž, Radić A, et al. (2017) The Effect of Intra-articular Injection of Autologous Microfragmented Fat Tissue on Proteoglycan Synthesis in Patients with Knee Osteoarthritis. Genes (Basel). 8: 270
    View at Publisher | View at Google Scholar
  47. Pers Y-M, Rackwitz L, Ferreira R, Pullig O, Delfour C, et al. (2016) Adipose Mesenchymal Stromal Cell-Based Therapy for Severe Osteoarthritis of the Knee: A Phase I Dose-Escalation Trial. Stem Cells Transl Med. 5: 847-856.
    View at Publisher | View at Google Scholar
  48. Berman et al. (2019) Prospective Study of Autologous Adipose Derived Stromal Vascular Fraction Containing Stem Cells for the Treatment of Knee Osteoarthritis. Int J Stem Cell Res Ther. 6(1):064.
    View at Publisher | View at Google Scholar
  49. Lapuente et al. (2020) Intra-articular infiltration of adipose-derived stromal vascular fraction cells slows the clinical progression of moderate-severe knee osteoarthritis: hypothesis on the regulatory role of intra-articular adipose tissue. Journal of Orthopaedic Surgery and Research. 15:137.
    View at Publisher | View at Google Scholar
  50. Simunec D, Salari H, Meyer J. (2020) Treatment of Grade 3 and 4 Osteoarthritis with Intraoperatively Separated Adipose Tissue-Derived Stromal Vascular Fraction: A Comparative Case Series. Cells. 9(9):2096.
    View at Publisher | View at Google Scholar
  51. Koh YG, Jo SB, Kwon OR, et al. (2013) Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. Arthrosc J Arthrosc Relat Surg Of Publ Arthroscopy Assoc N Am Int Arthrosc Assoc. 29:748-755.
    View at Publisher | View at Google Scholar
  52. Koh YG, Kwon OR, Kim YS, Choi YJ. (2014) Comparative outcomes of open-wedge high tibial osteotomy with platelet-rich plasma alone or in combination with mesenchymal stem cell treatment: a prospective study. Arthroscopy; 30:1453-1460.
    View at Publisher | View at Google Scholar
  53. Koh YG, Choi YJ, Kwon OR, Kim YS. (2014) Second-look arthroscopic evaluation of cartilage lesions after mesenchymal stem cell implantation in osteoarthritic knees. Am J Sports Med. 42:1628-1637.
    View at Publisher | View at Google Scholar
  54. Koh YG, Choi YJ, Kwon SK, Kim YS, Yeo JE. (2015) Clinical results and second-look arthroscopic findings after treatment with adipose-derived stem cells for knee osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 23:1308-1316.
    View at Publisher | View at Google Scholar
  55. Roato I., Belisario DC, Compagno M., et al. Concentrated adipose tissue infusion for the treatment of knee osteoarthritis: clinical and histological observations. International Orthopaedics. 43(1):15-23.
    View at Publisher | View at Google Scholar
  56. Jones IA, Wilson M, Togashi R, Han B, Mircheff AK, and C. Thomas Vangsness JR. (2018) A randomized, controlled study to evaluate the efficacy of intra-articular, autologous adipose tissue injections for the treatment of mild-to-moderate knee osteoarthritis compared to hyaluronic acid: a study protocol. BMC Musculoskeletal Disorders. 19(1):383.
    View at Publisher | View at Google Scholar
  57. Bui KH-T, Duong TD, Nguyen NT, et al. (2014) Symptomatic knee osteoarthritis treatment using autologous adipose derived stem cells and platelet-rich plasma: a clinical study. Biomedical Research and Therapy. 1(1):2.
    View at Publisher | View at Google Scholar
  58. Nguyen PD, TD-X. Tran, Nguyen, H. T.-N., et al. (2017) Comparative clinical observation of arthroscopic microfracture in the presence and absence of a stromal vascular fraction injection for osteoarthritis. Stem Cells Translational Medicine. 6(1):187-195.
    View at Publisher | View at Google Scholar
  59. Kim YS, Choi YJ, Koh YG. (2015) Mesenchymal stem cell implantation in knee osteoarthritis: an assessment of the factors influencing clinical outcomes. Am J Sports Med. 43:2293-2301.
    View at Publisher | View at Google Scholar
  60. Kim YS, Choi YJ, Suh DS et al. (2015) Mesenchymal stem cell implantation in osteoarthritic knees: is fibrin glue effective as a scaffold? Am J Sports Med. 43:176-185.
    View at Publisher | View at Google Scholar
  61. Di Matteo B. and Kon E. (2019) Editorial commentary: biologic products for cartilage regeneration-time to redefine the rules of the game? Arthroscopy: The Journal of Arthroscopic & Related Surgery. 35(1):260-261.
    View at Publisher | View at Google Scholar
  62. Hadley CJ, Shi WJ, Murphy H., Tjoumakaris FP, Salvo JP, and Freedman KB. (2019) The clinical evidence behind biologic therapies promoted at Annual Orthopaedic meetings: a systematic review. Arthroscopy: The Journal of Arthroscopic & Related Surgery. 35(1):251-259.
    View at Publisher | View at Google Scholar
  63. Hong Z, Chen J, Zhang S, et al. (2019) Intra-articular injection of autologous adipose-derived stromal vascular fractions for knee osteoarthritis: a double-blind randomized self-controlled trial. International Orthopaedics. 43(5):1123-1134.
    View at Publisher | View at Google Scholar
  64. Gimble JM, Katz AJ, and Bunnell BA. (2007) Adipose-derived stem cells for regenerative medicine. Circulation Research. 100(9);1249-1260.
    View at Publisher | View at Google Scholar
  65. Zuk PA, Zhu M., Ashjian P et al. (2002) Human adipose tissue is a source of multipotent stem cells. Molecular Biology of the Cell. 13(12):4279-4295.
    View at Publisher | View at Google Scholar
  66. Aust L, Devlin B, Foster SJ et al. (2004) Yield of human adipose derived adult stem cells from liposuction aspirates. Cytotherapy. 6(1):7-14.
    View at Publisher | View at Google Scholar
  67. Oedayrajsingh-Varma MJ, Van Ham SM, Knippenberg M. et al. (2006) Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure. Cytotherapy. 8(2):166-177.
    View at Publisher | View at Google Scholar
  68. Pak J, Lee JH, Kartolo WA, Lee SH. (2016) Cartilage Regeneration in Human with Adipose Tissue-Derived Stem Cells: Current Status in Clinical Implications. Biomed Res Int. 4702674.
    View at Publisher | View at Google Scholar
  69. Taniguchi Y, Yoshioka T, Sugaya H, Gosho M, Aoto K, et al. (2019) Growth factor levels in leukocyte-poor platelet-rich plasma and correlations with donor age, gender, and platelets in the Japanese population. J Exp Orthop.
    View at Publisher | View at Google Scholar
a